Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 19 2017 - 07:00AM
Akari Therapeutics (NASDAQ:AKTX), an emerging growth,
clinical-stage biopharmaceutical company, is pleased to announce
its Chief Executive Officer Dr. David Horn Solomon and Chief
Operations Officer Clive Richardson will present at the Cantor
Fitzgerald Global Healthcare Conference on Tuesday September 26,
2017 in New York City. The presentation is scheduled for 10:55am.
To access the live webcast of the presentation, visit the
Investor Relations section of Akari Therapeutics at
www.akaritx.com.
Akari is focused on the development and commercialization of
treatments for a range of rare and orphan autoimmune and
inflammatory diseases caused by the dysregulation of complement C5
and/or leukotriene B4 (LTB4).
About Akari Therapeutics Plc
Akari is a biopharmaceutical company focused on the development
and commercialization of innovative therapeutics to treat orphan
autoimmune and inflammatory diseases, in particular those where the
complement system or leukotrienes or both complement and
leukotrienes together play a primary role in disease progression.
Akari’s lead drug candidate Coversin is a C5 complement inhibitor
currently being evaluated in paroxysmal nocturnal hemoglobinuria
(PNH) and atypical hemolytic uremic syndrome (aHUS). In addition to
its C5 inhibitory activity, Coversin independently and specifically
inhibits leukotriene B4 (LTB4) activity. Akari intends to evaluate
Coversin in two conditions, the skin and eye diseases bullous
pemphigoid and atopic keratoconjunctivitis, where the dual action
of Coversin on both C5 and LTB4 may be beneficial. Akari is also
developing other tick derived proteins, including long acting
versions.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control. Such risks and uncertainties for our company
include, but are not limited to: needs for additional capital to
fund our operations, an inability or delay in obtaining required
regulatory approvals for Coversin and any other product candidates,
which may result in unexpected cost expenditures; risks inherent in
drug development in general; uncertainties in obtaining successful
clinical results for Coversin and any other product candidates and
unexpected costs that may result therefrom; failure to realize any
value of Coversin and any other product candidates developed and
being developed in light of inherent risks and difficulties
involved in successfully bringing product candidates to market;
inability to develop new product candidates and support existing
product candidates; the approval by the FDA and EMA and any other
similar foreign regulatory authorities of other competing or
superior products brought to market; risks resulting from
unforeseen side effects; risk that the market for Coversin may not
be as large as expected; inability to obtain, maintain and enforce
patents and other intellectual property rights or the unexpected
costs associated with such enforcement or litigation; inability to
obtain and maintain commercial manufacturing arrangements with
third party manufacturers or establish commercial scale
manufacturing capabilities; the inability to timely source adequate
supply of our active pharmaceutical ingredients from third party
manufacturers on whom the company depends; our inability to obtain
additional capital on acceptable terms, or at all; unexpected cost
increases and pricing pressures; uncertainties of cash flows and
inability to meet working capital needs; and risks and other risk
factors detailed in our public filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 20-F filed
on March 31, 2017. Except as otherwise noted, these forward-looking
statements speak only as of the date of this press release and we
undertake no obligation to update or revise any of these statements
to reflect events or circumstances occurring after this press
release. We caution investors not to place considerable reliance on
the forward-looking statements contained in this press release.
For more information
Investor Contact:
The Trout Group
Tricia Truehart
ttruehart@troutgroup.com
+1 646 378 2953
Media Contact:
Mary-Jane Elliott / Sukaina Virji
Consilium Strategic Communications
+44 (0)20 3709 5700
Akari@consilium-comms.com
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2023 to Mar 2024